BPC-157 + TB-500 Dual-Peptide Blend: Research Data
A conservative review of the 5 mg BPC-157 + 5 mg TB-500 co-formulated research vial: why investigators stack the two compounds, how little human combination data exists (four patients in one uncontrolled 2021 chart review, and no trial of the pair), the RFK-driven FDA review backdrop, and the July 23-24 2026 PCAC compounding docket.
Update History ▾
May 28, 2026: Added the April 2026 FDA regulatory update and the July 23–24 2026 PCAC 503A Bulks List review of BPC-157 and TB-500 (Category 2 wording corrected October 7, 2026).
May 27, 2026: Initial publication framing the BPC-157 + TB-500 blend as complementary (not synergistic) co-administration. Surfaces the explicit absence of peer-reviewed human combination data in 2025-2026. Cites the NBC News April 2026 reporting on RFK-driven FDA review and the July 23-24 2026 FDA PCAC hearing. Links out to the dedicated BPC-157 and TB-500 mechanism articles.
The BPC-157 + TB-500 blend is a co-formulated 5 mg + 5 mg research vial that pairs two compounds with complementary preclinical mechanisms — and almost no human combination data: four patients in one uncontrolled 2021 chart review, and no trial of the pair.[8] BPC-157 carries the nitric-oxide, VEGF/eNOS angiogenic, and FAK-paxillin growth-factor literature.[1] TB-500, defined by FDA as the synthetic Thymosin Beta-4 fragment Ac-LKKTETQ, borrows its rationale from the G-actin-sequestration and cell-migration literature on full-length Thymosin Beta-4; the biological effects of the fragment itself have not been documented.[2][10][11] The pathways are non-overlapping, which is the published basis for co-administration in animal-model work — but no published Phase 2 or Phase 3 human trial of the combination exists, and no PubMed-indexed human pharmacokinetic profile of the blend exists either.[3] The U.S. regulatory backdrop is the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee hearing on BPC-157, TB-500, KPV, and MOTS-c (Docket FDA-2025-N-6895), partly driven by HHS Secretary Robert F. Kennedy Jr.'s public support for these peptides in the longevity community.[4][5]
What Is the BPC-157 + TB-500 Blend?
The blend is a single lyophilized research vial containing 5 mg BPC-157 co-formulated with 5 mg of the TB-500 synthetic Thymosin Beta-4 fragment. Total peptide content per vial is 10 mg. The two compounds are co-lyophilized rather than packaged in separate vials, which fixes the ratio at 1:1 by mass.
BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, MW 1419.55 g/mol) derived from a stable fragment of a protein originally isolated from human gastric juice. Its preclinical signal centres on tissue-repair models involving nitric oxide, VEGF/eNOS angiogenic signalling, and FAK-paxillin growth-factor activity. The deep mechanism walk-through lives in the dedicated BPC-157 healing peptide review.[1]
TB-500 is defined by FDA and the anti-doping literature as Ac-LKKTETQ, the N-acetylated Thymosin Beta-4 (Tβ4) fragment spanning residues 17–23 (889 g/mol, CAS 885340-08-9). Products sold under the name vary, and some contain or claim full-length Tβ4 (43 amino acids, 4,963.4 g/mol, CAS 77591-33-4), so a vial's COA mass is what identifies its contents.[10] Full-length Tβ4 is the principal G-actin-sequestering peptide in mammalian cells, and the actin-cytoskeleton, cell-migration and angiogenesis findings behind the TB-500 rationale come mainly from full-length Tβ4; the biological effects of TB-500 itself have not been documented.[11] The separately bioactive N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) peptide is Tβ4 residues 1–4 and is not part of TB-500. The deep mechanism walk-through lives in the dedicated TB-500 (Thymosin Beta-4 fragment) review.[2]
The job of this article is not to repeat either compound-level mechanism walkthrough. It is to explain why the two are stacked in a single vial format, what the combination evidence base actually says, and how a research reader should design a protocol around the blend rather than around either single-compound vial.
Why Researchers Stack the Two: Complementary Pathways
The published rationale for co-administering BPC-157 with TB-500 in animal-model repair work is mechanistic complementarity. The two compounds target distinct, non-overlapping biology, and the stack hypothesis is that addressing two pathway clusters simultaneously is informative in a way that neither single agent is on its own.
The pathway split is clean:
- BPC-157 — the vascular and stromal lane. Multiple rodent studies report that BPC-157 modulates the nitric-oxide system, upregulates VEGFR2 and downstream eNOS-mediated angiogenic signalling in endothelial-cell models, and activates focal-adhesion kinase / paxillin phosphorylation in tendon and fibroblast preparations. The recurring preclinical phenotype is improved perfusion and accelerated stromal repair in tendon, ligament, gut-mucosal, and vascular injury models.[1]
- TB-500 — the actin-cytoskeleton lane. Native Thymosin Beta-4 binds monomeric G-actin in a 1:1 complex, maintains the cytoplasmic G-actin pool, and modulates the G-actin / F-actin equilibrium during cytoskeletal remodelling. Functionally this is the building block of lamellipodial protrusion, fibroblast migration, and keratinocyte sheet movement — the cell-migration component of wound re-epithelialisation. These actin functions are documented for full-length Tβ4, not for the TB-500 fragment, whose own biological effects have not been documented.[11] A distinct strand of full-length Tβ4 research involves its AcSDKP N-terminal fragment, an endogenous regulator of haematopoietic stem-cell cycling and a separately characterised anti-fibrotic peptide that the TB-500 fragment does not contain.[2]
Read together, the stack hypothesis is that BPC-157 modulates the vascular and growth-factor signal underneath a repair site while TB-500 is assumed, by extrapolation from full-length Tβ4, to modulate the cytoskeletal-migration signal at the cell level. The two effects are mechanistically additive in concept — angiogenesis plus actin-driven cell migration are recognised cooperating components of wound repair in standard cell-biology textbooks — but cooperative pathway logic and demonstrated clinical superiority are not the same claim.
This is exactly why "synergy" is the wrong word here. Synergy is a specific pharmacological claim that requires combination data showing the joint effect exceeds the additive sum of the two single-agent effects. No such combination dataset has been published for BPC-157 + TB-500. Until one is, the honest description of the stack is "complementary co-administration" rather than "synergy." Any source using "synergy" without that caveat is going past the published evidence.
| Attribute | BPC-157 | TB-500 (thymosin β-4 fragment) |
|---|---|---|
| Class | Synthetic pentadecapeptide (15 aa) | Synthetic thymosin β-4 fragment, defined as Ac-LKKTETQ (residues 17–23); products sold under the name vary |
| Primary research focus (preclinical) | Tendon, ligament, GI and soft-tissue models | Actin regulation, cell migration, tissue repair (data mostly from full-length thymosin β-4) |
| Mechanism most studied | Nitric-oxide pathway, angiogenesis, growth factors | Actin sequestration / cell migration, documented for full-length thymosin β-4; TB-500's own effects not documented |
| Human evidence | Very limited | Very limited |
| Blend (combination) evidence | No controlled human trials of the BPC-157 + TB-500 blend | No controlled human trials of the BPC-157 + TB-500 blend |
| Regulatory status | Not approved — research use only | Not approved — research use only |
The Combination Evidence Gap — No Controlled Human Trial (2025-2026)
This is the article's most important section. It does not get softened.
A PubMed search at the time of writing returns no human trial of BPC-157 combined with TB-500, and a ClinicalTrials.gov search returns no registered Phase 2 or Phase 3 trial of the combination at any stage. The only human combination data are four patients in an uncontrolled 2021 retrospective chart review of knee-pain patients at an Orlando, Florida clinic, who received BPC-157 with thymosin beta-4 in a form the paper does not specify (Lee and Padgett, PMID 34324435); there was no control group.[8] Otherwise the two compounds have been studied separately. BPC-157's human record is five small studies: two placebo-controlled enema studies from 2002–2005 reported only as conference abstracts (a 32-person phase 1 safety study and a 53-person ulcerative-colitis trial), and three uncontrolled pilot reports by one Florida physician (2021, 2024, 2025), the latest a two-subject IV safety pilot by Lee and Burgess that reported no measurable change in the markers it tested (PMID 40131143).[3] No controlled trial has shown efficacy: FDA's July 2026 briefing found the one randomised trial too thinly reported and exploratory to support effectiveness.[9] The RegeneRx RGN-259 ophthalmic programme has produced the Phase 3 ARISE-1, ARISE-2, and ARISE-3 dry-eye data for full-length Thymosin Beta-4[2] — but none of these is a controlled test of the combination, and RGN-259 is full-length Tβ4, not the "TB-500" synthetic fragment.
All combination-context material published in 2025-26 falls into one of three buckets:
- Preclinical co-administration work in animal models. A small body of rodent tendon and wound-healing literature has tested BPC-157 and Tβ4-derived fragments in the same protocol. These are preclinical signals that contribute to mechanism mapping, not human efficacy data.
- Clinic-practice anecdotal reporting. A non-trivial fraction of the "BPC + TB blend" content circulating in the longevity and recovery space is anecdotal clinic-practice reporting from compounding pharmacies and individual practitioners. This is not peer-reviewed evidence. It does not establish efficacy, dose, or safety at the human cohort level.
- Narrative review citation of the individual mechanisms. The McGuire et al. 2025 narrative review in Current Reviews in Musculoskeletal Medicine (PMC12446177) and equivalent reviews of Tβ4 cite the individual preclinical bodies for each compound. None of the three buckets contains a controlled combination dataset.
The honest summary: in 2026 the BPC-157 + TB-500 blend is a research-tool format with two well-characterised single-compound preclinical mechanisms and a combination evidence base that, in human terms, amounts to four patients in one uncontrolled 2021 chart review. That is not a critique of the format. It is the actual state of the literature, and any research catalog framing the blend should reflect it.
What the Preclinical Combination Literature Does Cover
The preclinical co-administration record is thin compared with the per-compound literature, but it exists. The few rodent and in-vitro studies that have tested BPC-157 with a Tβ4-derived fragment in parallel typically use one of three designs:
- Parallel-arm rodent injury models. One arm receives BPC-157 alone, one arm receives TB-500 alone, one arm receives both, and one arm receives vehicle. The endpoint is typically wound closure rate, histological repair score, or tensile-strength recovery in a tendon or skin model. The recurring observation is that each single-agent arm shows the per-compound signal already present in the larger literature; the combination arm generally tracks the better of the two single-agent arms rather than producing a clean super-additive effect. This is consistent with complementary pathway logic but does not demonstrate synergy in the formal pharmacological sense.
- In-vitro fibroblast and endothelial co-culture. Scratch-wound assays and tube-formation assays have been used with each compound individually, with combination work appearing in scattered cell-biology publications. The mechanism translation is consistent: BPC-157 contributes the angiogenic and FAK-paxillin signal, the Tβ4-derived peptide contributes the cell-migration signal.
- Compounding-pharmacy bench characterisation. Some compounding-pharmacy filings and bench-characterisation reports include analytical work on the co-lyophilised blend itself — HPLC retention, mass-spectrometry confirmation of both peptides, and physical-stability characterisation. This is reagent characterisation rather than pharmacology, but it is the most rigorous part of the public combination record at the moment.
What is missing from the published combination record is anything that closes the translation gap to humans: a registered combination trial, a pharmacokinetic profile of the co-administered pair, a dose-response surface for the combination, or a head-to-head comparison of the blend against either single-compound vial in a controlled human cohort. None of those exists in the indexed literature.
The FDA Compounding Review as Policy Backdrop
The U.S. regulatory backdrop for the BPC-157 + TB-500 conversation in 2026 is not the science of either compound. It is the FDA compounding-pharmacy review, and the politics around it.
NBC News reported in April 2026 that the FDA's evaluation of BPC-157 and TB-500 for inclusion on the 503A Bulks List is partly driven by HHS Secretary Robert F. Kennedy Jr.'s public support for both peptides in the longevity community.[5] That political layer is a published fact about the proceeding, not a clinical claim about either molecule.
For a research reader, the implication is straightforward. The U.S. regulatory environment around BPC-157 and TB-500 in 2026 is moving on a timeline driven partly by policy attention rather than purely by new clinical evidence — which means the published evidence base (preclinical signal, thin human record, no controlled combination study) is the same in May 2026 as it was in late 2025, even as the surrounding noise has increased. Research-use framing should track the evidence, not the noise.
Storage & Handling for the Blend
The blend is supplied as a lyophilized 10 mg total peptide vial (5 mg BPC-157 + 5 mg TB-500) and is handled like any other short-peptide research vial. The fact that two compounds share the vial does not change the storage chemistry:
- Storage of the lyophilisate. 2-8°C protected from light for routine use; -20°C for long-term storage. In warm climates, documented cold-chain handling from arrival to bench-side is important — short ambient excursions during last-mile delivery are the most common stability risk.
These notes describe the research-vial format only. The page provides no human-use dosing, preparation or veterinary instructions and is not a clinical-protocol document. Wider storage questions are covered in the peptide stability and storage guide.
What the Blend Literature Does Not Yet Give You
Cautious reading of the BPC-157 + TB-500 combination record requires acknowledging four real gaps.
- No registered human RCT of the blend. A ClinicalTrials.gov search at the time of writing returns no Phase 2 or Phase 3 trial registration for the BPC-157 + TB-500 combination at any indication. There is no head-to-head trial of the blend against either single-compound vial, and no placebo-controlled combination cohort.
- No published human pharmacokinetic profile of the combination. Distribution, clearance, half-life, and metabolite kinetics of the two peptides when co-administered are not characterised in the public literature. Each compound has only a thin individual PK record — the combination has none.
- No dose-response surface for the combination. The 1:1 mass ratio in the marketed 5 mg + 5 mg blend is a co-formulation convenience, not a published optimum. There is no preclinical dose-titration of the BPC-157 : TB-500 ratio that establishes 1:1 as the right blend ratio, and there is no human work that establishes any ratio.
- "Synergy" is not the published claim. The pathway logic supports complementary co-administration. It does not support a formal synergy claim, because no combination dataset has measured the joint effect against the predicted additive effect. Any source using "synergy" for the blend is going past the published evidence.
These gaps are not arguments against studying the combination. They are arguments against framing the blend as a validated stack while the human combination evidence is limited to four patients in one uncontrolled chart review.
BPC + TB-500 Blend Research-Use Supply & Format
For research use, the BPC-157 + TB-500 blend belongs in the category of co-formulated repair-signalling research peptides — supplied as a lyophilized 5 mg + 5 mg vial with cold-chain handling for in-vitro work, and — when in stock — shipped with the active lot reference confirmed before dispatch.
The BPC-157 + TB-500 blend vial page documents the catalog format, current pricing, and purity line. The two compounds are also available as separate research vials for investigators who need each compound on its own: the BPC-157 10mg research vial and the TB-500 10mg research vial ship under the same 2-8°C cold-chain handling. Researchers who want a fixed 1:1 mass ratio typically prefer the blend; researchers who need either compound on its own, or per-compound batch-reference tracking, typically prefer the separate vials.
Each vial is supplied to a >99% HPLC line standard for in-vitro research; published Janoshik batch reports across the Retatrutide range are indexed in the COA library, and Dubai sourcing checks are in the blend Dubai guide. For mechanism depth, the dedicated BPC-157 healing peptide review and TB-500 (Thymosin Beta-4 fragment) review remain the controlling references; this page sits on top of those two, framing the combination question rather than duplicating either compound walkthrough.
Material is supplied strictly for in-vitro laboratory research. It is not framed for human use, not framed for veterinary use, and not framed as a treatment.
Our Research Standards
This article prioritizes primary preclinical literature, PubMed and ClinicalTrials.gov negative-result searches, the public FDA docket, and named press reporting. Where the combination evidence record is absent, we say so directly. No therapeutic, human-use, or veterinary-use claim is made here. Read our editorial policy →
BPC + TB-500 Blend Research FAQ
What is in the BPC-157 + TB-500 research blend?
Each lyophilized vial contains 5 mg BPC-157 (CAS 137525-51-0, 15-amino-acid pentadecapeptide, MW 1419.55 g/mol) co-formulated with 5 mg of TB-500, which FDA and the anti-doping literature define as the synthetic Thymosin Beta-4 fragment Ac-LKKTETQ (Tβ4 residues 17–23, CAS 885340-08-9; full-length Tβ4 is CAS 77591-33-4). Products sold as TB-500 vary, so the COA mass is what identifies a vial's contents. Total 10 mg lyophilized peptide content per vial. It is supplied strictly for in-vitro laboratory research and is not an approved medicine.[1][2][10]
Why do researchers stack BPC-157 and TB-500 in one vial?
The rationale is mechanistic complementarity rather than published synergy. BPC-157's preclinical signal centres on nitric oxide signalling, VEGF/eNOS-driven angiogenesis, and FAK-paxillin growth-factor activity. TB-500 is studied as a Thymosin Beta-4 fragment, but the G-actin sequestration and cell-migration biology behind its rationale is documented for full-length Thymosin Beta-4; the biological effects of TB-500 itself have not been documented. The two are thought to act on distinct biology, which is why investigators sometimes co-administer them in animal-model repair work.[1][2][11]
Is the BPC-157 + TB-500 blend more effective than separate vials?
No published peer-reviewed human evidence supports that claim. There are no Phase 2 or Phase 3 clinical trials of the BPC-157 + TB-500 combination. The blend format is a co-formulation convenience for researchers running fixed-ratio in-vitro work; it is not a validated efficacy claim. Investigators who need either compound on its own should use the separate BPC-157 10mg research vial and TB-500 10mg research vial instead.
Are there peer-reviewed human trials of the BPC-157 + TB-500 combination?
No. No trial has tested BPC-157 together with TB-500: a PubMed and ClinicalTrials.gov search at the time of writing returns no combination trial, published or registered. The only human combination data are four patients in an uncontrolled 2021 retrospective chart review who received BPC-157 with thymosin beta-4, in a form the paper does not specify (Lee and Padgett, PMID 34324435). BPC-157's own human record is five small studies: two placebo-controlled enema studies from 2002–2005 reported only as conference abstracts, and three uncontrolled pilot reports by one Florida physician (2021, 2024 and 2025, the latest the Lee and Burgess two-subject IV safety pilot, PMID 40131143). Full-length Thymosin Beta-4 has its own RegeneRx RGN-259 ARISE Phase 3 ophthalmic programme. None of these is a controlled test of the combination.[3][8][9]
What is the FDA reviewing on July 23-24, 2026?
The FDA Pharmacy Compounding Advisory Committee reviewed BPC-157, TB-500, KPV, and MOTS-c for the 503A Bulks List on July 23-24, 2026 (Docket FDA-2025-N-6895). It voted to recommend BPC-157 for ulcerative colitis and TB-500 for wound healing (each reported 8 to 6 with one abstention), both against FDA reviewers' advice; the votes are non-binding and no final FDA action had been published as of October 7, 2026. NBC News reported in April 2026 that the review is partly driven by HHS Secretary Robert F. Kennedy Jr.'s public support for these peptides in the longevity community. Research-use supply is not affected.[4][5][7]
How is the BPC-157 + TB-500 blend stored?
The lyophilized blend vial is stored at 2-8°C, protected from light, with long-term storage at -20°C. In warm climates, documented cold-chain handling from arrival to the bench is the main stability safeguard.
How is the BPC-157 + TB-500 blend supplied for research use?
Remy Research supplies the BPC-157 + TB-500 blend as a lyophilized 5 mg + 5 mg research vial under 2-8°C cold-chain handling, with tracked cold-chain delivery when in stock. The blend is supplied strictly for in-vitro laboratory research only. It is not framed for human use, veterinary use, or therapeutic application. The active lot reference can be confirmed before dispatch. The blend is supplied to a >99% HPLC line standard for in-vitro research; published Janoshik COAs across the Retatrutide range are indexed in the COA library.
Sources
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. doi: 10.2174/1570159X13666160502153022 · PMID: 27138887. See also Hsieh MJ et al., J Mol Med 2017;95(3):323-333 on the VEGFR2 pathway, PMID: 27847966. Mechanism depth in the dedicated BPC-157 review. ↩
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi: 10.1517/14712598.2012.634793 · PMID: 22074294. Bock-Marquette I et al., Nature 2004;432(7016):466-472 on cardiac repair, PMID: 15565145. Mechanism depth in the dedicated TB-500 review. ↩
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC: PMC12446177. Neither paper tests the BPC-157 + TB-500 combination. ↩
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — agenda and docket FDA-2025-N-6895. fda.gov advisory committee calendar ↩
- NBC News (NBC Miami). FDA weighs loosening restrictions on peptides as longevity community — and RFK Jr. — pushes for access. April 2026. nbcmiami.com/news/national-international/fda-peptides-weighs-loosen-restrictions-longevity-rfk-jr/3796345/ ↩
- Reuters. US FDA to convene expert panel to review wider access to some peptides. April 15, 2026. reuters.com. Federal Register notice 2026-07361, April 16 2026 (PCAC July 23–24 2026 docket). ↩
- Choi J. FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists. The Hill. July 23, 2026. thehill.com ↩
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435. Retrospective chart review with no control group; 4 of the 16 patients reached received BPC-157 combined with thymosin beta-4 (form not stated). ↩
- U.S. Food and Drug Administration. FDA briefing document on BPC-157 (ulcerative colitis), Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026. fda.gov/media/193343. Reviews five human studies: two placebo-controlled studies published only as meeting abstracts (Veljaca et al. 2002/2003; Ruenzi et al. 2005) and three uncontrolled pilot reports (Lee and Padgett 2021; Lee, Walker and Ayadi 2024; Lee and Burgess 2025). ↩
- U.S. Food and Drug Administration. FDA briefing document on TB-500 (wound healing), Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026. fda.gov/media/193349. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PMID: 23084823. Delcourt V, Garcia P, Chabot B, et al. Equine Doping Controls of Thymosin β4: A Population Study and Strategy for Misuse Detection. Drug Test Anal. 2025;17(7):1071-1077. PMID: 39314109. ↩
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. doi: 10.1016/j.jchromb.2024.124033 · PMID: 38382158. ↩
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Updated April 22, 2026. fda.gov. Lists BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" under "Bulk drug substances nominated but withdrawn". FDA 503A bulk drug substances category list, May 14, 2026: fda.gov/media/94155. ↩
For product-format details, see the BPC-157 + TB-500 blend vial, the BPC-157 10mg research vial, and the TB-500 10mg research vial. For sourcing checks, continue to the blend Dubai guide and the COA library.